Physician profile
Ambreen Khurshid
NPI 1265490551
$1,990.20
in general payments reported to CMS, 2019-2025
14 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $173 · 2021: $245 · 2022: $661 · 2023: $521 · 2024: $82.81 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $632.65 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $477.89 | 2019-2022 | |
| Abbvie INC. | $319.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $110.17 | 2023 | Farxiga |
| Regeneron Pharmaceuticals, INC. | $107.14 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.00 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $60.03 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.95 | 2021-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $47.19 | 2024 | Resmetirom |
| Aimmune Therapeutics, INC. | $31.31 | 2025 | Zenpep, Vowst |
| Vivus LLC | $26.66 | 2019 | |
| Alfasigma USA, INC. | $25.00 | 2020 | |
| Ardelyx, INC. | $15.92 | 2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambreen Khurshid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.